1. Home
  2. SGI vs UTHR Comparison

SGI vs UTHR Comparison

Compare SGI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGI

Somnigroup International Inc.

HOLD

Current Price

$73.82

Market Cap

20.2B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$532.23

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGI
UTHR
Founded
1846
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.2B
23.9B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
SGI
UTHR
Price
$73.82
$532.23
Analyst Decision
Strong Buy
Buy
Analyst Count
5
14
Target Price
$102.00
$533.21
AVG Volume (30 Days)
2.1M
545.2K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
0.91%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$7.08
$7.05
Revenue Next Year
$5.21
$13.30
P/E Ratio
$48.98
$19.44
Revenue Growth
N/A
2.38
52 Week Low
$53.10
$266.98
52 Week High
$98.56
$549.50

Technical Indicators

Market Signals
Indicator
SGI
UTHR
Relative Strength Index (RSI) 33.88 56.84
Support Level $69.78 $464.92
Resistance Level $75.06 $542.66
Average True Range (ATR) 2.75 13.43
MACD -0.05 -0.45
Stochastic Oscillator 25.19 55.83

Price Performance

Historical Comparison
SGI
UTHR

About SGI Somnigroup International Inc.

Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: